glp-1 diet software The Reset Best Food Log App for

The Legal Arguments Plaintiffs Claim: Manufacturers (Novo Nordisk, Eli Lilly) knew or should have known about risks of gastroparesis and NAION Warning labels failed to adequately disclose these serious side effects Drugs were aggressively marketed as safe and effective weight loss solutions without proper risk disclosure Patients would not have taken the medications had they known the true risks Defendants Respond: Claims are unfounded (Novo Nordisk statement) Will defend vigorously against lawsuits Motion to dismiss expected January 24, 2025 Argue that labels were adequate and that many conditions may be pre-existing or related to diabetes itself Whos Most at Risk

2001;131(3s):955S-962S

Olumuyide et al., 2026 (International Journal of Obesity) argues for integration: use the pharmacologic advantage (appetite suppression, fat loss) to create space for sustainable behavior change

Aleman Dr

Although research is currently limited, Anna talks about what we know so far and her experience with clients taking these drugs in clinical practice